Drs. Maryleen Lovell-Petronilia is a Medical Biologist specialized in Molecular Pathology with more than 14 years of experience in clinical research, healthcare, Quality Assurance, and Compliance. Throughout her career, she has demonstrated strategic leadership, a commitment to operational excellence, and a proven ability to drive sustainable quality improvements within highly regulated environments.

Following a distinguished 10-year tenure in Research & Innovation, during which she successfully introduced risk management practices into routine clinical diagnostics, Maryleen transitioned into leadership roles focused on Quality & Compliance. Since 2022, she has led global Quality Assurance & Compliance at EmVenio Clinical Research (formerly PCM Trials), driving quality oversight, regulatory compliance, and continuous improvement across international operations.

A passionate advocate for patient-centric clinical research, Maryleen is dedicated to advancing more accessible, inclusive, and efficient clinical trials by reducing participant and site burden and supporting improved participant enrollment and retention. She promotes innovative approaches that bring clinical trials closer to participants while safeguarding their safety, rights, and well-being. With a strong focus on navigating the evolving global regulatory landscape and understanding the implications of applicable guidelines, including ICH E6 (R3) GCP, she champions compliant and sustainable solutions that support decentralized clinical trials and global mobile healthcare delivery. Through collaboration, innovation, and risk-based thinking, Maryleen fosters Trust with participants, Sites and Sponsors while driving initiatives that uphold the highest standards of quality, data integrity, information security, regulatory compliance, and operational excellence.